After Alzheimer's agitation nod, Axsome jacks up Auvelity's peak sales projection to $8B

Summary: Axsome Therapeutics just got great news! Their drug, Auvelity, is now approved by the FDA to treat agitation in Alzheimer's disease. It was already being used to treat depression. Because of this new approval, the company believes Auvelity could eventually make up to $8 billion in sales.

Investors were thrilled, and the company's stock price shot up 23% after the announcement. Auvelity is special because it is the first non-antipsychotic pill for Alzheimer's agitation, giving it a big advantage over its main competitor, which carries a strict safety warning.

Source: Fierce Pharma URL: fiercepharma.com/pharma/after-alzheimers-agitation-nod-axsome-jacks-auvelitys-peak-sales-projection-8b (opens in new tab)